Simply Wall St.
How Recent Developments Are Rewriting The Story For Coherus Oncology (CHRS)
📊
AI Sentiment
Positive
7/10
- Home
- CHRS
as of 02-18-2026 3:55pm EST
$1.63
+$0.01
+0.93%
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
| Founded: | 2010 | Country: | N/A |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 186.0M | IPO Year: | N/A |
| Target Price: | $5.51 | AVG Volume (30 days): | 3.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $0.71 - $2.62 | Next Earning Date: | 01-01-0001 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | -83.41% | Revenue Growth (next year): | 79.63% |
| P/E Ratio: | 1.20 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
AI-Powered CHRS Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 21 hours ago
AI Recommendation
hold
Model Accuracy: 77.07%
77.07%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Coherus BioSciences Inc. News
CHRS Breaking Stock News: Dive into CHRS Ticker-Specific Updates for Smart Investing
GlobeNewswire
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
📈
AI Sentiment
Highly Positive
8/10
MT Newswires
Coherus BioSciences Prices $50.1 Million Share Offering
📉
AI Sentiment
Negative
3/10
GlobeNewswire
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
âž–
AI Sentiment
Neutral
4/10
GlobeNewswire
Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock
âž–
AI Sentiment
Neutral
4/10
Compare CHRS vs Leading Stocks
See how CHRS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CHRS Coherus BioSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.